
    
      Before the approval of IBRANCEÂ® in Korea, as a part of Risk Management Plan (RMP), which is
      required by Ministry of Food and Drug Safety (MFDS), safety and efficacy information of new
      medication will be provided at minimum 3000 subjects administered in the setting of routine
      practice during the initial 6 years after the approval.
    
  